7 Results for "

trabectedin

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "trabectedin" in MCE Product Catalog:

Cat. No.: HY-172664A
Target:  

Drug Derivative

Domaines de recherche:  

Cancer

Trabectedin derivative 2 TFA (compound PL-12) is a Trabectedin derivative that can be used for the study of cancer .
Cat. No.: HY-172663A
Domaines de recherche:  

Cancer

Trabectedin derivative 1 TFA is a selective DNA minor groove binder. Trabectedin derivative 1 TFA inhibits DNA transcription and repair to induce tumor cell apoptosis. Trabectedin derivative 1 TFA is promising for research of solid tumors such as soft tissue sarcoma and ovarian cancer .
Cat. No.: HY-172664
CAS No.: 3056692-81-7
Target:  

Drug Derivative

Domaines de recherche:  

Cancer

Trabectedin derivative 2 (compound PL-12) is a trabectedin derivative that can be used in research on ovarian cancer, gastric cancer, and breast cancer .
Cat. No.: HY-50936S
Synonyms: Ecteinascidin 743-d3; ET-743-d3
Trabectedin D3 (Ecteinascidin 743 D3) is deuterium labeled Trabectedin. Trabectedin is a tetrahydroisoquinoline alkaloid with potent antitumor activity. Trabectedin binds to the minor groove of DNA, blocks transcription of stress-induced proteins, induces DNA backbone cleavage and cancer cells apoptosis, and increases the generation of ROS in MCF-7 and MDA-MB-453 cells. Trabectedin has tje potential for soft tissue sarcoma and ovarian cancer treatment .
Cat. No.: HY-171715
CAS No.: 3056740-00-9
Domaines de recherche:  

Cancer

PL-13 (Compound P11) is the derivative of Trabectedin. PL-13 can disrupt the function of DNA and induces apoptosis in cancer cells. PL-13 be can be used for the research of cancer .
Cat. No.: HY-177966
CAS No.: 250159-76-3
Domaines de recherche:  

Cancer

ETM-305 is a degradation product of the anticancer agent ET-743 (HY-50936). ET-743 (Ecteinascidin 743; Trabectedin) is a tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA, blocks the transcription of stress-induced proteins, induces DNA backbone cleavage and cancer cell apoptosis, and increases ROS production in MCF-7 and MDA-MB-453 cells. Trabectedin is used in the research of soft tissue sarcoma and ovarian cancer .
Cat. No.: HY-L143
61 compounds

Oceans cover more than 70% of the Earth’s surface and host a huge species diversity. Marine organisms are considered the most recent source of bioactive natural products after terrestrial plants and nonmarine microorganisms. Marine biological sources are taxonomically diverse and include sponges, tunicates, corals, mollusks, fungi, and sediment-derived bacteria.

Marine organisms can produce a plethora of small molecules with novel chemical structures and potent biological properties, being a rich source for the discovery of pharmacologically active compounds, already with several marine-derived agents approved as drugs. Ziconotide, a peptide originally discovered in a tropical cone snail, was the first marine-derived compound to be approved in the United States in December 2004 for the treatment of pain. Then, in October 2007, Trabectedin became the first marine anticancer drug to be approved in the European Union.

MCE offers a unique collection of 61 marine-sourced natural products which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE marine-sourced natural product library is an important source for drug discovery and development.